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Abstract
Aims/hypothesis Lysosomal acid lipase (LAL) hydrolyses
cholesteryl esters and triacylglycerols (TG) within lysosomes
to mobilise NEFA and cholesterol. Since LAL-deficient (Lal-/-)
mice suffer from progressive loss of adipose tissue and severe
accumulation of lipids in hepatic lysosomes, we hypothesised
that LAL deficiency triggers alternative energy pathway(s).
Methods We studied metabolic adaptations in Lal-/- mice.
Results Despite loss of adipose tissue, Lal-/- mice show en-
hanced glucose clearance during insulin and glucose tolerance
tests and have increased uptake of [3H]2-deoxy-D-glucose
into skeletal muscle compared with wild-type mice. In agree-
ment, fasted Lal-/- mice exhibit reduced glucose and glycogen
levels in skeletal muscle. We observed 84% decreased plasma
leptin levels and significantly reduced hepatic ATP, glucose,
glycogen and glutamine concentrations in fed Lal-/- mice.
Markedly reduced hepatic acyl-CoA concentrations decrease
the expression of peroxisome proliferator-activated receptor α
(PPARα) target genes. However, treatment of Lal-/-mice with
the PPARα agonist fenofibrate further decreased plasma TG
(and hepatic glucose and glycogen) concentrations in Lal-/-
mice. Depletion of hepatic nuclear factor 4α and forkhead
box protein a2 in fasted Lal-/- mice might be responsible for
reduced expression of microsomal TG transfer protein, defec-
tive VLDL synthesis and drastically reduced plasma TG
levels.
Conclusions/interpretation Our findings indicate that neither
activation nor inactivation of PPARα per se but rather the
availability of hepatic acyl-CoA concentrations regulates
VLDL synthesis and subsequent metabolic adaptations in
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Lal-/- mice. We conclude that decreased plasma VLDL pro-
duction enhances glucose uptake into skeletal muscle to com-
pensate for the lack of energy supply.
Keywords Glucose tolerance . Lipolysis . Lysosomes .
VLDL
Abbreviations
BW Body weight
CE Cholesteryl ester
CESD Cholesteryl ester storage disease
FPLC Fast protein liquid chromatography
H&E Haematoxylin and eosin
ITT Insulin tolerance test
LAL Lysosomal acid lipase
PLIN2 Perilipin 2
PPARα Peroxisome proliferator-activated receptor α
scWAT subcutaneous white adipose tissue
TC Total cholesterol
TG Triacylglycerol
TLC Thin-layer chromatography
WAT White adipose tissue
WD Wolman disease
WT Wild-type
Introduction
Lysosomal acid lipase (LAL) hydrolyses cholesteryl esters
(CE) and triacylglycerols (TG), delivered to the lysosome
mainly via LDL particle uptake [1], to release mono- and diac-
ylglycerols and mobilise cholesterol and NEFA for membrane
assembly, steroidogenesis and energy production. Genetic mu-
tations of human LAL (also known as LIPA) cause an autosomal
recessive lysosomal storage disorder with accumulation of CE
predominantly in hepatocytes, adrenal glands, intestine and
cells of the monocyte-macrophage system throughout the body
[2]. Mutations in LAL cause Wolman disease (WD) or
cholesteryl ester storage disease (CESD) [3–5]. WD is a rare,
neonatal-onset disease with less than 1% of LAL activity,
characterised by massive hepatosplenomegaly, adrenal calcifi-
cations, malabsorption, growth retardation and cachexia.
Affected patients die within the first three to 12 months of life
[2, 6, 7]. CESD patients have up to 5% residual LAL activity
[8], which keeps the syndrome mostly unrecognised until
adulthood. These patients suffer from progressive lysosomal
CE and TG accumulations, which lead to the characteristic liver
pathology and elevated concentrations of serum transaminases,
serum LDL and TG. Premature death of individuals with
CESD is due to liver failure and/or accelerated atherosclerosis
rather than to chronic hyperlipidaemia [2, 9, 10].
In contrast to humans, complete loss of LAL activity in
mice phenotypically resembles CESD rather than WD.
LAL-deficient (Lal-/-) mice appear normal at birth and reach
the median life span of approximately 1 year [11]. Severe
accumulations of CE and TG are found predominantly in the
liver, spleen, small intestine and adrenals [11–13]. Lal-/- mice
exhibit reduced size and body weight (BW) compared with
wild-type (WT) littermates as well as progressive loss of white
adipose tissue (WAT) and brown adipose tissue [12, 13]. In
this study, we explored the metabolic changes caused by im-
paired lysosomal TG and CE hydrolysis in Lal-/- mice.
Methods
Animals Age- and sex-matched Lal-/- and WT littermates [13]
on a C57BL/6J background were maintained with unlimited
access to chow and water in regular 12 h light/12 h dark cycles.
For fenofibrate treatment, 5-week-old Lal-/- mice were adminis-
tered 0.2% fenofibrate/chow for 4 weeks. Experimenters were
blind to group assignment and outcome assessment. Animal
experiments were approved by the Federal Ministry of
Science, Research and Economy, Vienna, Austria. See electronic
supplementary material (ESM) Methods for further details.
Lipid and hormone concentrations and fast protein liquid
chromatography Cholesterol, TG, glycerol and markers of
liver injury were quantified enzymatically. Lipoprotein pro-
files were analysed by fast protein liquid chromatography
(FPLC) [14]. Hormones were determined by ELISA. See
ESM Methods for further details.
ATP analysis Polar metabolites from mouse liver were ex-
tracted as described previously [15]. HPLC was performed on
a 1100 Agilent capillary LC (Agilent Technologies, Santa
Clara, CA, USA) equipped with a polyhydroxyethyl column
(PolyLC Inc, Columbia, MD, USA). Solvent A (10 mmol/l
ammonium acetate/water) and solvent B (10 mmol/l ammoni-
um acetate/90% acetonitrile) were used in varying gradients.
Selected ions/fragments were detected by TSQQuantumUltra
Mass Spectrometry (Thermo Fisher Scientific, Waltham, MA,
USA) in negative mode. See ESMMethods for further details.
De novo lipid synthesis Animals were i.p. injected with
[14C]acetate (5 μCi in 200 μl PBS), killed 1 h post-injection,
and livers were isolated and lyophilised for 48 h. Lipid ex-
tracts were separated by thin-layer chromatography (TLC)
(n-hexane:diethylether:acetic acid; 80:20:2, vol.:vol.:vol.).
Radioactivity in bands corresponding to NEFA, TG, non-
esterified cholesterol and CE was determined by liquid scin-
tillation counting.
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Liver acyl-CoAs Acyl-CoAs were extracted from liver lysate
homogenates using 0.5 ml of buffer (50% 0.1 mol/l KH2PO4,
50% 2-propanol; 4°C), 30 μl saturated (NH4)2SO4 and 0.5 ml
acetonitrile, and centrifuged (2,500 g, 10 min, 4°C). Acyl-
CoAs were determined by liquid chromatography-mass spec-
trometry as described previously [16]. See ESM Methods for
further details.
Neutral TG hydrolase activityNeutral TG hydrolase activity
was measured as described previously [17], with minor mod-
ifications as described in ESM Methods.
Mitochondria isolation and respirometry Liver mitochon-
dria were isolated as described previously [18] and resuspended
in medium. Mitochondria were diluted in medium plus 0.2%
NEFA-free BSA, 5 mmol/l glutamate, 1 mmol/l malate, or
5 mmol/l pyruvate, 5 mmol/l succinate, 1 μmol/l rotenone.
Oxygen consumption rates were measured at 37°C (Oxygraph-
2k; Oroboros Instruments, Innsbruck, Austria). State 3-
respiration (mitochondrial respiration due to ADP supply) and
state 4o-respiration (after ATP synthase inhibition by oligomycin)
were induced by 2 mmol/l ADP and 1 μg/ml oligomycin.
Maximal uncoupled respiration was determined after titration of
carbonyl cyanide p-trifluoromethoxyphenylhydrazone. See ESM
Methods for further details.
RNA isolation and quantitative real-time PCR analysis
RNA isolation and quantitative real-time PCR were per-
formed as described previously [19]. See ESM Methods for
primer sequences and further details.
VLDL secretion Mice (8 h-fasted) were i.p. injected with
500 mg/kg BW tyloxapol in PBS. Plasma TG were deter-
mined every hour post-injection.
Tolerance tests Mice were i.p. injected with glucose (2 g/kg
BW), insulin (0.25 U/kg BW), glucagon (140 μg/kg BW),
glycerol (2 g/kg BW), pyruvate (2 g/kg BW) and glutamine
(2 g/kg BW). Blood glucose levels were determined using
Accu-Chek Active glucometer (Roche Diagnostics,
Mannheim, Germany). See ESM Methods for further details.
[3H]2-deoxy-D-glucose uptake Mice (6 h-fasted) were i.p.
injected with 30 mg glucose and 0.5 μCi glucose per 30 g
BW. Radioactivity in 40 μl plasma (15, 30 and 60 min post-
injection) and tissue lysates was determined by β-counting.
See ESM Methods for further details.
Quantification of metabolites by nuclear magnetic reso-
nance spectroscopy Liver and skeletal muscle lysates
(200 μl) were mixed with methanol (400 μl), incubated at
−20°C (30 min) and centrifuged. Supernatants were dried
and re-dissolved in 500 μl D2O.
1H-one-dimensional-nuclear
magnetic resonance experiments were performed at 310 K.
Reference chemical shifts were taken from the Madison-
Qingdao Metabolomics Consortium Database (http://mmcd.
nmrfam.wisc.edu/) [20]. Bruker Topspin3.1 (Rheinstetten,
Germany) and MestReNova10.0 software (http://mestrelab.
com) were used for data acquisition, processing and
analyses. See ESM Methods for further details.
In vivo MRI for body fat MR images of anesthetised mice
were acquired by 3T-MRI (Siemens Tim-Trio, Erlangen,
Germany) with an eight-channel multipurpose coil (Noras
MRI products, Hoechenberg, Germany).
Western blotting Protein samples were separated by SDS-
PAGE and transferred to polyvinylidene-difluoride mem-
branes. Blots were incubated with primary antibodies follow-
ed by HRP-conjugated secondary antibodies. See ESM
Methods for further details.
Subcutaneous WAT sections Tissue samples were fixed in
4% paraformaldehyde and embedded in paraffin. Tissue sec-
tions (4μm)were stained with haematoxylin and eosin (H&E)
and evaluated by light microscopy.
Electron microscopy Liver sections were fixed in phosphate
buffer/2.5% glutaraldehyde, washed, post-fixed in phosphate
buffer/OsO4 for 1 h and 4×10 min in phosphate buffer. After
dehydration, tissues were infiltrated (acetone and agar 100
epoxy resin, pure agar 100 epoxy resin) for 4 h, placed in agar
100 epoxy resin (8 h), transferred into embedding moulds, and
allowed to polymerise (48 h, 60°C). Sections stained with lead
citrate and uranyl acetate were imaged. See ESMMethods for
further details.
Statistics Since Lal-/- mice were obviously much smaller than
WT mice, in vivo experiments were not blind. In vitro exper-
iments were blind to group assignment and outcome assess-
ment. Statistical analyses were performed using GraphPad
Prism 5.04 (GraphPad Software, San Diego, CA, USA).
Significant outliers were detected by Grubb’s test (http://
graphpad.com/quickcalcs/Grubbs1.cfm). Significances were
determined by Student’s unpaired t test and Welch correction
(in case of unequal variances) for two group comparison and
ANOVA followed by Bonferroni correction for multiple group
comparison. Data are presented as means ± SD. Differences
were considered statistically significant at p<0.05.
Results
Decreased acyl-CoA concentrations and peroxisome
proliferator-activated receptor α signalling in Lal-/- liver
We observed severe accumulation of total cholesterol (TC)
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and TG in livers of Lal-/- mice (Fig. 1a, b). Livers of WT mice
store lipids within cytosolic lipid droplets, whereas in Lal-/-
mice lipids were entrapped within lysosomes distinguished by
bilayer membranes (Fig. 1a). In addition, a substantial number
of cholesterol crystals were visible. TG and CE could not be
hydrolysed and remained entrapped within the lysosomes
(Fig. 1b). Reduced protein expression of perilipin 2 (PLIN2)
and reduced neutral TG hydrolase activity indicated a reduced
number of cytoplasmic lipid droplets in Lal-/- livers (Fig. 1c).
In accordance, acyl-CoA concentrations were reduced in
livers of Lal-/- mice, with markedly decreased acetyl-,
palmitoleoyl-, oleoyl- and linoleoyl-CoA levels (Fig. 1d).
Consistently, we observed decreased mRNA expression of
fatty acid binding protein 1 (Fabp1) (Fig. 1e). Increased
mRNA expression of cluster of differentiation 36 (Cd36) but
unaltered expression of LDL receptor (Ldlr) suggested
increased NEFA and unchanged LDL uptake, respectively
(Fig. 1e). Moreover, de novo cholesterol synthesis was in-
duced in Lal-/- livers as indicated by increased expression of
hydroxymethylglutaryl-CoA reductase (Hmgcr) (Fig. 1e) and
a moderate increase in hepatic cholesterol synthesis after i.p.
injection of [14C]acetate (Fig. 1f). By contrast, de novo pro-
duction of TG, CE and NEFA was significantly reduced in
Lal-/- livers (Fig. 1f). mRNA levels of selected peroxisome
proliferator-activated receptor α (PPARα) target genes were
markedly decreased in Lal-/- compared with WT livers
(Fig. 1g), which is in line with decreased acyl-CoA
concentrations.
Intact mitochondrial function despite decreased ATP con-
centrations in Lal-/- livers Since insufficient supply of NEFA
and, consequently, acyl-CoA may affect mitochondrial func-
tion and energy production, we next investigated the hepatic
mitochondria of Lal-/- mice. Unaltered mitochondrial mor-
phology (Fig. 2a) and a comparable amount of mitochondrial
DNA (ESM Fig. 1a) indicated functional mitochondria. The
respiratory capacity of mitochondria isolated from Lal-/- livers
was decreased only for the uncoupled state when succinate
Fig. 1 Reduced concentrations of liver acyl-CoAs in Lal-/- mice. (a)
Electron micrographs ofWTand Lal-/- liver. White arrows, lipid droplets;
white arrowheads, fatty lysosomes; scale bar, 1 μm. (b) Hepatic TG and
TC concentrations (n= 3). (c) Hepatic expression of PLIN2 with GAPDH
as loading control, and hepatic neutral TG hydrolase activity. (d) Liver
acyl-CoA concentrations (n = 4–5 mice aged 7–9 weeks). (e) Hepatic
mRNA expression of fatty acid binding protein 1 (Fabp1), cluster of
differentiation 36 (Cd36), LDL receptor (Ldlr) and 3-hydroxy-3-methyl-
glutaryl-CoA reductase (Hmgcr) (n= 5–6). (f) Hepatic incorporation of
i.p. injected [14C]acetate into lipid classes after TLC separation (n = 5
mice aged 17–20 weeks); FC, non-esterified cholesterol. (g) mRNA ex-
pression of acyl-CoA thioesterase1 (Acot1), cytochrome P450, family4,
subfamily a, polypeptide31 (Cyp4a31), acyl-CoA oxidase1 (Acox1), very
long-chain (Vlcad) and medium chain acyl-CoA dehydrogenase (Mcad;
also known as Acadm) (n = 4–5). Data represent means ± SD; *p < 0.05,
**p ≤ 0.01, ***p ≤ 0.001, Student’s unpaired t test. If not stated otherwise,
mice were 12–16 weeks of age. Black bars, WT mice; white bars, Lal-/-
mice
Fig. 2 Intact mitochondria and reduced ATP concentrations in Lal-/-
livers. (a) Electron micrographs of mitochondria in livers of WT and
Lal-/- mice aged 12 weeks; scale bar, 0.5 μm. (b) Mitochondrial respira-
tion of mitochondria isolated from WT and Lal-/- livers (n= 4–6) using
10 mmol/l succinate/1 μmol/l rotenone as substrates. Oxygen consump-
tion rate presented as basal mitochondrial respiration in the presence of
substrates (basal), increased mitochondrial respiration due to ADP supply
(state 3), after ATP synthase inhibition by oligomycin (state 4o) and after
carbonyl cyanide p-trifluoromethoxyphenylhydrazone addition
(uncoupled). (c) Liver ATP concentrations determined by liquid chroma-
tography-tandem mass spectrometry (n= 5–6 mice aged 8–12 weeks).
Data represent means ± SD; *p < 0.05, **p ≤ 0.01, Student’s unpaired t
test. Black bars, WT mice; white bars, Lal-/- mice. OCR, oxygen con-
sumption rate
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was provided as substrate (Fig. 2b) but unaltered with gluta-
mate in the presence of malate (ESM Fig. 1b) or pyruvate
(ESM Fig. 1c). These data suggest that the lack of substrate
(acyl-CoA) might be responsible for reduced ATP concentra-
tions in Lal-/- livers (Fig. 2c).
Diminished VLDL secretion in Lal-/- mice Since Lal-/- mice
suffer from progressive loss of adipose tissue, we expected
lipid metabolism during fasting to be severely affected.
Interestingly, fasting failed to increase circulating TG concen-
trations in Lal-/- mice (Fig. 3a), whereas TC was increased in
Lal-/- mice regardless of the feeding state. Plasma lipoprotein
profiles of fasted Lal-/-mice revealed increased levels of LDL-
cholesterol and decreased levels of HDL-cholesterol (Fig. 3b).
However, in contrast to WT mice, Lal-/- mice failed to induce
VLDL-TG during fasting, with redistribution of TG toward
the LDL fraction (Fig. 3c). Biochemical estimation confirmed
the FPLC data, showing no difference after 4 h and reduced
plasma TG concentrations after 12 h of fasting (Fig. 3d).
We next investigated VLDL secretion after inhibition of
peripheral lipolysis by tyloxapol and found strongly reduced
VLDL release in fasted Lal-/-mice (Fig. 3e). As expected, Lal-/-
mice showed markedly increased concentrations of amino-
transferases (ESM Fig. 2), an indication of liver damage.
Hepatic mRNA expression of microsomal TG transfer protein
(Mttp), a key player in VLDL assembly, was decreased
(Fig. 3f). Drastically reduced mRNA and protein expression
of the hepatic transcription factors hepatocyte nuclear factor
4a (Hnf4a) and forkhead box protein a2 (Foxa2) (Fig. 3f, g),
which are involved in VLDL synthesis [21, 22], reflect a causal
link between low expression levels of these transcription fac-
tors and decreased VLDL secretion in Lal-/- livers.
Increased insulin sensitivity in Lal-/- mice Severe impair-
ment of lipid metabolism in Lal-/- mice and reduced acyl-
CoA and TG availability prompted us to investigate metabolic
adaptations to defective lipid metabolism. Intraperitoneal glu-
cose tolerance tests and insulin tolerance tests (ITT) revealed
significantly improved glucose tolerance (Fig. 4a) and insulin
sensitivity (Fig. 4b) in Lal-/-mice. Plasma glucose levels were
reduced (Fig. 4c), whereas insulin levels were comparable
between Lal-/- and WT mice (Fig. 4d). These data indicate
Fig. 3 Abolished nuclear expression of HNF4α and FOXA2 and de-
creased VLDL synthesis in Lal-/- mice. (a) Plasma TG and TC concen-
trations in 12 h fasted (n= 5) and fed mice (n= 7–9). Distribution of (b)
TC and (c) TG within plasma lipoproteins (n = 6); continuous lines, WT;
dotted lines, Lal-/-; red lines, 4 h fasting; black lines, 12 h fasting. (d)
Plasma TG concentrations of 4 h and 12 h fasted mice (n = 5). (e) VLDL
secretion of 8 h fasted mice (n= 4–7) after tyloxapol injection. (f) Hepatic
mRNA expression of microsomal TG transfer protein (Mttp), hepatic
nuclear factor 4α (Hnf4a) and forkhead box protein a2 (Foxa2) (n = 5–
6). (g) Immunoblotting against liver HNF4a and FOXA2 (both in fasted
state) in cytosolic (C) and nuclear (N) fractions with GAPDH and
LaminA/C as loading controls. Data represent means ± SD; *p < 0.05,
**p ≤ 0.01, ***p ≤ 0.001. (a, d, f) Student’s unpaired t test, (e) ANOVA.
Mice were aged 12–16 weeks. Black bars and squares, WT mice; white
bars and squares, Lal-/- mice
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increased usage of glucose in Lal-/- mice. Accordingly, the up-
take of i.p. injected [3H]2-deoxy-D-glucose into skeletal muscles
was increased by 1.9-fold in Lal-/- mice (Fig. 4e). [3H]2-deoxy-
D-glucose uptake by Lal-/- livers (Fig. 4e) as well as radioactivity
in plasma (Fig. 4f) were comparable between both genotypes.
mRNA expression of glycolysis genes in skeletal muscles were
comparable in fed (Fig. 4g) and reduced in fasted Lal-/- mice
(Fig. 4h). In agreement, glucose and glycogen concentrations
were decreased in fasted Lal-/- mice (Fig. 4i), whereas muscle
lactate was reduced in both fed and fasted states.
Decreased plasma leptin concentrations and altered ex-
pression of hepatic adiponectin and leptin receptors in
Lal-/- mice Despite comparable food intake, Lal-/- mice were
lighter and gained less weight (ESM Fig. 3a, b). They lacked
visceral fat and exhibited markedly reduced subcutaneous (sc)
WAT at the age of 4 and 12 weeks (ESM Fig. 3c). H&E
staining of scWAT sections revealed smaller adipocytes with
reduced fat content (Fig. 5a) and we observed reduced ingui-
nal scWAT mass (Fig. 5b) in Lal-/- mice. Adipose tissue fun-
damentally influences systemic insulin sensitivity and glucose
metabolism via the adipokines leptin and adiponectin [23].
Leptin mRNA expression was significantly decreased in
scWAT of Lal-/- compared with WT mice, whereas
adiponectin mRNA expression was unchanged (Fig. 5c).
Since fasting significantly decreases basal leptin levels [24],
decreased plasma leptin concentrations (84%) in fed Lal-/-
mice but comparable levels as WT mice after fasting
(Fig. 5d) indicate that feeding is ineffective to increase the
satiety hormone leptin in Lal-/- mice. Plasma adiponectin
levels were comparable between both genotypes (Fig. 5e).
mRNA expression of the leptin receptors (Leptr)1 and 2 were
markedly increased in livers of fed (Fig. 5f) and fasted
(Fig. 5g) Lal-/- mice. Expression of adiponectin receptor
(Adipor)1 mRNA was higher and expression of Adipor2
mRNA was lower in livers of fed Lal-/- mice than WT fed
mice (Fig. 5f). While Adipor1 mRNA levels were similar in
fasted livers of both genotypes, transcript levels of Adipor2
Fig. 4 Improved glucose tolerance and insulin sensitivity in Lal-/- mice.
Plasma glucose concentrations in (a) 6 h fasted and (b) 4 h fasted mice
(n = 5) after i.p. injection of (a) glucose (2 g/kg) and (b) insulin (0.25
U/kg). Concentrations of (c) plasma glucose in 6 h fasted (n= 14) and fed
(n = 7) mice and (d) insulin in 4 h fasted and fed mice (n = 4). (e)
Radioactivity in skeletal muscle, liver and (f) plasma of mice (n= 5) after
i.p. injection of [3H]2-deoxy-D-glucose. mRNA expression of glycogen
synthase1 (Gys1), glycogen phosphorylase (Pygm), hexokinase 1 (Hk1),
phosphofructokinase (Pfkm), fructose-biphosphatase2 (Fbp2) and pyru-
vate kinase (Pkm) in skeletal muscles of (g) fed and (h) 12 h fasted mice
(n = 4–5). (i) Skeletal muscle metabolites of fed and 12 h fasted mice
(n = 5). Data represent means ± SD; *p < 0.05, **p ≤ 0.01,
***p ≤ 0.001. (a, b, f) ANOVA, (c–e, g–i) Student’s unpaired t test.
Mice were aged 12–16 weeks. Black bars and squares, WT mice; white
bars and squares, Lal-/- mice
Fig. 5 Reduced scWAT and plasma leptin concentrations in Lal-/- mice.
(a) H&E staining of inguinal scWAT sections. (b) scWAT mass normal-
ised to BW (n= 6). (c) mRNA expression of leptin (Lep) and adiponectin
(Adipoq) in scWAT (n= 4–5). Plasma concentrations of (d) leptin and (e)
adiponectin (n= 6). mRNA expression of the receptors of hepatic leptin
(Leptr) and adiponectin (Adipor) in (f) fed and (g) 12 h fasted WT and
Lal-/- mice (n = 3–5). Data represent means ± SD; *p< 0.05, **p ≤ 0.01;
***p ≤ 0.001, Student’s unpaired t test. Mice were aged 12–16 weeks.
Black bars, WT mice; white bars, Lal-/- mice
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were reduced in livers of Lal-/-mice compared withWT livers
(Fig. 5g).
Reduced liver glucose, glycogen and glutamine concentra-
tions in Lal-/- mice Significantly reduced plasma glycerol
concentrations in fasted Lal-/- mice indicate diminished pe-
ripheral lipolysis (Fig. 6a). Reduced liver glycogen concentra-
tions in fed Lal-/- mice (Fig. 6b) were confirmed by decreased
mobilisation of glucose from glycogen after i.p. injection of
glucagon (Fig. 6c). Reduced liver storage of glucose is a result
of ineffective production or extensive usage. We therefore
determined the ability of Lal-/- mice to produce glucose from
different carbon sources. After i.p. injection of glycerol, de
novo synthesised glucose reached similar maximal values af-
ter 30 min in WT and after 15 min in Lal-/- mice (Fig. 6d).
Thus, glucose was cleared faster from the circulation in Lal-/-
mice as shown by significantly decreased levels after 60 min,
implying increased systemic glucose usage. Gluconeogenesis
as measured by pyruvate tolerance test was unaltered
(Fig. 6e), but drastically decreased in Lal-/- mice after i.p.
injection of glutamine (Fig. 6f). In line, hepatic glucose and
glutamine concentrations were markedly reduced in livers of
fed Lal-/- mice (Fig. 6g), whereas lactate and pyruvate levels
were comparable to those in WT mice. Decreased hepatic
glucose content may be a reason why (with the exception of
liver-specific phosphofructokinase [Pfkl]) the mRNA expres-
sion levels of all other liver enzymes involved in glycolysis
were reduced in Lal-/- livers (Fig. 6h).
PPARα activation reduces liver glucose and glycogen as
well as plasma TG concentrations in Lal-/- mice To investi-
gate whether alterations in glucose homeostasis and VLDL
synthesis in Lal-/- mice are mediated by diminished PPARα
activation, Lal-/- mice were fed fenofibrate for 4 weeks. We
observed decreased hepatic glucose and completely depleted
glycogen content in fenofibrate-treated Lal-/- mice (Fig. 7a).
Lactate concentrations in the liver were unaffected, whereas
plasma lactate levels were reduced (Fig. 7b). Moreover,
fenofibrate treatment reduced liver TC and plasma TG con-
centrations (Fig. 7c, d). We further found induced expression
of the PPARα targets Cyp4a31 and Vlcad (also known as
Acadvl), reduced Adipor1 transcript level and increased ex-
pression of Leptr1 (Fig. 7e). Importantly, relative mRNA ex-
pression levels ofMttp, Hnf4a and Foxa2 remained compara-
ble between untreated and fenofibrate-treated Lal-/- mice. We
conclude that defective VLDL synthesis in Lal-/- mice is a
Fig. 6 Reduced glycogen, glucose and glutamine concentrations in Lal-/-
livers. (a) Plasma glycerol in fasted (n= 5) and (b) liver glycogen con-
centrations in fed mice (n = 8). (c–f) Glucose concentrations after i.p.
injection of (c) glucagon (140 μg/kg BW), (d) glycerol (2 g/kg BW),
(e) pyruvate (2 g/kg BW) and (f) glutamine (2 g/kg BW) in plasma of
(c) fed and (d–f) fasted mice (n= 5–7). (g) Liver metabolites in fed mice
(n = 6). (h) mRNA expression of glucokinase (Gck), phosphofructokinase
(Pfkl), fructose-biphosphatase 1 (Fbp1), aldolase B (Aldob), phospho-
glycerate kinase 1 (Pgk1), pyruvate kinase 1 (Pk1), glucose-6-phosphate
dehydrogenase (G6pd; also known as G6pdx), glycogen phosphorylase
(Pygl), glycerol-3-phosphate dehydrogenase1 (Gpd1) and pyruvate dehy-
drogenase (Pdhb) (n = 6–9). Data represent means ± SD; *p < 0.05,
**p ≤ 0.01, ***p ≤ 0.001. (a, b, g, h) Student’s unpaired t test, (c–f)
ANOVA. Mice were aged 12–18 weeks. Black bars and squares, WT
mice; white bars and squares, Lal-/- mice
Fig. 7 Reduced plasma TG and liver glucose and glycogen in
fenofibrate-treated Lal-/- mice. Five-week-old Lal-/- mice were adminis-
tered fenofibrate (0.2%) for 4 weeks. (a) Hepatic lactate, glucose and
glycogen, and (b) plasma lactate and glucose concentrations (n= 5). TG
and TC concentrations in (c) liver and (d) plasma (n = 4). (e) mRNA
expression of cytochrome P450, family4, subfamily a, polypeptide 31
(Cyp4a31), very long-chain chain acyl-CoA dehydrogenase (Vlcad),
adiponectin receptors (Adipor1 and 2), leptin receptor 1 (Leptr1), hepatic
nuclear factor 4α (Hnf4a), forkhead box protein a2 (Foxa2) and micro-
somal TG transfer protein (Mttp) (n= 3–4). Data represent means ± SD;
*p< 0.05, **p ≤ 0.01, ***p ≤ 0.001. Student’s unpaired t test. Black bars,
Lal-/- mice; white bars, fenofibrate-treated Lal-/- mice
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consequence of diminished hepatic HNF4α/FOXA2 signal-
ling rather than PPARα inactivation.
Discussion
The appearance of hepatic ‘fatty lysosomes’ in insulin-sensitive
Lal-/-mice contrasts with hepatosteatosis, in which accumulation
of cytoplasmic lipid droplets is accompanied by insulin resis-
tance [25–27]. Liver is the main organ for VLDL assembly
and secretion and thus influences whole body TG and cholester-
ol homeostasis [28]. Skop et al have already suggested the in-
volvement of LAL in VLDL synthesis [29]. The authors linked
the process to autophagy, since inhibition of lysosomal activity
by chloroquine decreased VLDL secretion in vitro. Our in vivo
data, however, indicate that defective VLDL synthesis in Lal-/-
mice is a consequence of decreased hepatic availability of acyl-
CoAs, which then leads to downregulation of PPARα signalling,
nuclear exclusion ofHNFα and FOXA2, decreasedMttp expres-
sion, reduced TG synthesis, and eventually futile lipidation of
ApoB [21, 22, 30, 31]. In general, PPARα activation mediates
lipid oxidation and reduces ectopic lipid storage, thereby
counteracting insulin resistance [32]. Interestingly, Lal-/- mice
show reduced expression of PPARα target genes, yet produce
less VLDL, which contrasts with the increased secretion of
VLDL observed in Ppara-/- mice [33]. However, fenofibrate
treatment did not normalise the phenotype but further decreased
plasma TG (and hepatic glucose and glycogen) concentrations in
Lal-/- mice. These findings indicate that neither activation nor
inactivation of PPARα per se but rather the availability of hepatic
acyl-CoAs regulates VLDL synthesis and subsequent metabolic
adaptations.
HNF4α, a key regulator of various metabolic pathways, is
classified as an orphan receptor despite NEFA being sug-
gested as its endogenous ligand [34]. In fact, Yuan et al dem-
onstrated that HNF4α is selectively associated with linoleic
acid in mammalian cells and in the liver of fed mice [35],
indicating that linoleic acid is at least one possible endogenous
ligand for HNF4α. Nuclear exclusion of HNF4α together
with a 60% reduction in 18:2-CoA in livers of Lal-/- mice
suggest that lysosomal mobilisation of linoleic acid is in-
volved in VLDL synthesis via the HNF4α pathway.
Accordingly, protein expression of FOXA2, which is con-
trolled by insulin signalling [36] and promotes VLDL synthe-
sis [21], was significantly reduced in Lal-/- liver. Besides re-
duced VLDL secretion, Lal-/- mice had increased insulin sen-
sitivity compared with their WT littermates. This finding is in
accordance with studies in animal models [37, 38] and type 2
diabetes patients [39], indicating a connection between insulin
resistance and VLDL overproduction. We thus propose that
reduced plasma VLDL is one of the features to induce a shift
from NEFA to glucose utilisation, resulting in improved insu-
lin sensitivity as observed by enhanced uptake of glucose in
skeletal muscles of these mice. Although non-significant, a
35% increase of skeletal muscle glycogen in fed Lal-/- mice
indicates enhanced storage of glucose for energy supply dur-
ing fasting.
WAT is a primary contributor to metabolic regulation during
feeding and fasting. Although lipodystrophy is generally asso-
ciated with insulin resistance [40], Lal-/- mice show reduced
plasma glucose and enhanced glucose usage. Despite substan-
tial loss of WAT mass in Lal-/- mice, plasma concentrations of
adiponectin were comparable, whereas leptin levels were pro-
foundly decreased after feeding. These findings indicate that
Lal-/- mice have a constant energy demand due to the unavail-
ability of NEFA fromWATcytosolic lipid droplets. Diminished
VLDL synthesis induces depletion of liver energy storage
pools as reflected by reduced liver glycogen, glucose and glu-
tamine concentrations. Decreased liver glucose levels may be
causative for lower hepatic mRNA expression of genes in-
volved in glycolysis, particularly of Gck and Pk1 (also known
as Pklr). The liver provides glucose through gluconeogenesis
from non-carbohydrate precursors during prolonged fasting
[41]. Lal-/- mice, however, are unable to produce glucose from
external glutamine, suggesting that the degradation of gluta-
mine to pyruvate is defective. However, gluconeogenesis
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Fig. 8 Decreased hepatic acyl-CoA availability reduces VLDL synthesis
and triggers insulin sensitivity in Lal-/- mice. Inhibited hepatic lysosomal
hydrolysis of CE and TG due to LAL deficiency leads to reduced abun-
dance of cellular acyl-CoA and ATP. Consequently, decreased expression
of the PPARα targets, HNF4α, FOXA2 and Mttp results in defective
hepatic VLDL secretion. Decreased plasma glucose and leptin, and re-
duced liver glucose, glycogen and glutamine concentrations in fed Lal-/-
mice indicate increased energy demand and extensive systemic usage of
glucose. Treatment with the PPARα agonist fenofibrate further reduces
plasma TG, liver glucose and glycogen concentrations in Lal-/- mice,
indicating that VLDL synthesis and insulin sensitivity is PPARα-inde-
pendent. Decreased VLDL production might be a consequence of re-
duced hepatic acyl-CoA concentrations, particularly the HNF4a ligand
linoleic acid (18:2). Glucose tolerance and insulin sensitivity are in-
creased to compensate for decreased energy availability
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per se is functional, as shown by unaltered pyruvate tol-
erance tests. Glycerol tolerance test revealed earlier max-
imal glucose levels and glucose was cleared faster from
the circulation, confirming enhanced glucose utilisation
in Lal-/- mice.
We conclude that defective lysosomal hydrolysis of CE and
TG decreases hepatic acyl-CoA and ATP concentrations.
Consequently, abolished nuclear expression of HNF4α and
FOXA2 lead to reduced Mttp expression and attenuated
VLDL secretion, which in turn induces insulin sensitivity
(Fig. 8). During the past 30–40 years, our understanding of
proteins and lipids that influence VLDL assembly and secre-
tion has changed tremendously [42]. We argue that LAL
should be included as another critical player, which regulates
VLDL and glucose metabolism.
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